

A large, stylized DNA double helix structure is the central visual element, rendered in a gradient from blue at the top to orange at the bottom. The background is a dark blue to purple gradient with a subtle pattern of white dots, resembling a starry sky or a molecular lattice.

Viral vector solutions **that move your program forward**

Process Development • Manufacturing • Cell Banking
Analytical Services • Drug Product Filling • Regulatory Support
for AAV, LV-based, Adeno and other viral modalities

Integrated Viral Vector Solutions

Accelerate your programs from innovative process development to commercial success with leading-edge viral vector manufacturing solutions.

SK pharmteco delivers advanced viral vector manufacturing solutions to support programs from early development through commercial production. Our capabilities span process development, CGMP and non-CGMP manufacturing, analytical testing, and regulatory support. With expertise in AAV, LV-based, Adeno, and other viral modalities including oncolytic viruses, herpesviruses, retroviruses, and other emerging therapies., we provide scalable, flexible solutions designed to accelerate development and enable reliable commercialization, bringing your life-changing therapies to patients faster and more efficiently.

SKyvec™ Viral Vector Platform

SKyvec AAV

Flexible, HEK293-based AAV manufacturing supporting programs of diverse serotypes and transgenes, from early research through clinical supply, with high yield, adherent and suspension processes, and integrated analytical capabilities. Leveraging the SKyvec AAV platform alongside fully tailored solutions enable rapid, reliable, and regulatory-ready progression.

SKyvec Lenti

Supporting *ex vivo* and *in vivo* programs from early development through commercialization, with proven adherent and suspension processes, high productivity, and integrated analytical capabilities. Our SKyvec Lentiviral platform and flexible, customized solutions ensure accelerated development and reliable scale-up.

SKyvec Adeno

Robust adaptable adenoviral vector manufacturing supporting programs from early development through commercialization, with scalable adherent and suspension processes, optimized yields, and integrated analytical capabilities.

Flexible solutions to advance your program at **every stage**

With the goal of efficiently solving your manufacturing challenges, SK pharmteco offers viral vector manufacturing solutions designed for reliable, high-quality process development and production.

Our capabilities include high-throughput drug substance production (both adherent and suspension), advanced drug product manufacturing suites, and integrated testing services to support your program platform assays for AAV, lentivirus, adenovirus and other viruses, as well as stability programs. Additionally, our experts can help you navigate the complex regulatory landscape, for an efficient pathway to bring your product into the market.



Adapting to your specific needs, our state-of-the-art facilities can accommodate:



Personalized services with processes tailored to your requirements, providing a customized solution that enhances your project's success.



Streamlined development to deliver faster, more reliable outcomes for your therapeutic innovations.

3 plug-and-play viral vector manufacturing platforms

9 vector suites + Formulation and Fill & Finish suites

100+

number of total CGMP batches produced over AAV, Lentivirus and other viral vectors

Ex vivo LVV to in vivo LVV

vector intermediate to final drug product

Up to

1,000 L

suspension process

Up to


500 L

adherent process

100% Commercial-Ready

SK pharmteco facilities are designed by former regulators to meet clinical and commercial quality standards, and each suite supports both clinical and commercial supply to accelerate speed to market upon regulatory approval.





Fill/Finish Capabilities

SK pharmteco provides specialized drug product formulation and aseptic fill & finish services tailored for viral vectors. Our dedicated fill & finish suites in both France and the U.S., are designed to minimize product loss, ensuring efficient handling of small-volume, high-value therapies. By combining deep formulation expertise with scalable, reliable fill & finish operations, we help accelerate development timelines, reduce contamination risks, and support seamless tech transfers. This ensures your viral vector therapies reach patients efficiently, safely, and in full compliance.



Regulatory and Quality Support

- Expert regulatory support for gene therapy CDMO programs, guiding clients from clinical trials through commercialization, ensuring global compliance and successful regulatory submissions.
- Offer control and oversight at all stages of the product life cycle including IND and BLA submission preparation and guidance, marketing authorization approval, amendment, and supplement submission packages, briefing document packages, strong relationships with global health authorities to expedite regulatory success.
- Access to automated, globally compliant gene therapy quality assurance program that ensures phase-appropriate compliance and commercial readiness for our development partners' advanced therapy programs. Our advanced, integrated data infrastructure provides a fully digital footprint throughout development and manufacturing, giving our clients a transparent view into every step of every process including real-time data capture, electronic batch records, and predictive analytics to track CQAs and CPAs.

Complete CDMO Solutions for Biotech and Pharma Success

In the fast-paced world of pharma and biotech, efficiency is everything. From process development and high-throughput drug substance manufacturing to drug product filling, testing, and enabling services, we are your complete partner, ensuring smooth transitions from development to commercialization. Let us help streamline your path to market with our fully integrated offerings.



Easy to Work With:

Streamlined onboarding with straightforward contracts, transparent terms, and a clear sample submission process. We aim to deliver proposals in less than two weeks and begin processing samples immediately upon receiving a purchase order.



Prioritized Delivery:

Our team is committed to on-time, in-full delivery to ensure that your project progresses smoothly without unnecessary rush or delays.



Strong Communication:

Benefit from having direct access to the technical lead driving your project. This agile approach ensures your needs are communicated and addressed quickly and effectively.



Integrated Sample Management:

Seamlessly manage sample transfers for secure and efficient handling throughout your journey.



Want to learn more about our
Integrated Viral Vector Solutions?

Scan here or visit <https://www.skpharmteco.com/viral-vectors/>



About SK pharmteco:

SK pharmteco is a global contract development and manufacturing organization (CDMO) serving the pharmaceutical and biopharmaceutical industries. With CGMP manufacturing sites, research and development facilities, and analytical laboratories across the United States, Europe, and South Korea, the company provides integrated services spanning Active Pharmaceutical Ingredients (APIs), advanced intermediates, registered starting materials, viral vectors for gene therapy, and analytical capabilities in support of client programs. SK pharmteco partners with companies of all sizes to enable the development and delivery of transformative therapies worldwide. The company is a subsidiary of SK Inc. (KRX: 034730), the strategic investment arm of SK Group, South Korea's second-largest conglomerate.

